-
Why Perrigo Is Divesting Rights To The Best Multiple Sclerosis Drug
Thursday, March 2, 2017 - 4:38pm | 604Read More...Perrigo Company plc Ordinary Shares (NYSE: PRGO) announced on Monday it would divest its rights to the royalty stream from the global net sales of multiple sclerosis drug Tysabri in favor of privately-held Royalty Pharma. Tysabri is a drug used to treat multiple sclerosis, or MS, a...
-
Merger Monday Strikes Again (OMC, SKS, PRGO, ELN)
Monday, July 29, 2013 - 9:28am | 1214Read More...Merger Monday struck this morning as several high profile deals were announced heading into this week's trading. Notable deals included the merger of Omnicom (NYSE: OMC) and Publicis (OTC: PUBGY), Saks (NYSE: SKS) being bought by Canada's Hudson's Bay, and Perrigo (NYSE: PRGO) buying Elan (NYSE:...
-
Jefferies Raises PT on Elan to $19
Wednesday, July 6, 2011 - 9:18am | 122Read More...Jefferies is out with its report today on Elan (NYSE: ELN), raising its PT from $12 to $19. In a note to clients, Jefferies writes, "Now that Elan has almost doubled since we initiated in January, much has changed that we feel warrants an increase in our price target from $12 to $19. Concerns...
